IMpassion130 Efficacy Results in First-Line PD-L1+ Metastatic Triple-Negative Breast Cancer

Significantly improved progression-free survival (PFS) with TECENTRIQ + nab-paclitaxel (nab-pac)

40% reduced risk of disease progression or death with TECENTRIQ + nab-pac vs placebo + nab-pac 2

CI=confidence interval; HR=hazard ratio; NE=not estimable; PD-L1=programmed death-ligand 1.

  • 1-year PFS was 29% with TECENTRIQ + nab-pac vs 16% with placebo + nab-pac (not prespecified and not powered to demonstrate statistically significant differences) 3

Test for PD-L1 to identify patients who could benefit from TECENTRIQ + nab-pac in mTNBC

Select Important Safety Information

Serious and sometimes fatal adverse reactions occurred with TECENTRIQ treatment. Warnings and precautions include immune-mediated serious adverse reactions, including pneumonitis, hepatitis, colitis, endocrinopathies, and other immune-mediated adverse reactions. Other warnings and precautions include infections, infusion-related reactions, and embryo-fetal toxicity.

Please see below and the TECENTRIQ Prescribing Information for additional Important Safety Information.

TECENTRIQ + nab-pac: response achieved in more patients vs placebo + nab-pac

More than half of patients responded to TECENTRIQ + nab-pac 2*

1L=first-line; CR=complete response; DoR=duration of response; mTNBC=metastatic triple-negative breast cancer; ORR=objective response rate; PR=partial response.
*Confirmed responses in patients with measurable disease at baseline.

  • 9% of patients (17/185) had a complete response to TECENTRIQ + nab-pac vs <1% (1/183) with placebo + nab-pac
  • Median DoR was 9.2 months (95% CI, 7.5, 11.9) with TECENTRIQ + nab-pac vs 6.2 months (95% CI, 5.5, 8.8) with placebo + nab-pac